When did REIG JOFRE announce the European launch of dalbavancin?

REIG JOFRE announced the launch on 2026-06-10. The announcement covers the first three months of dalbavancin’s commercialisation, during which the treatment was made available to hospitals across nine European countries.

How many dalbavancin vials did REIG JOFRE make available to hospitals?

REIG JOFRE said that nearly 20,000 vials were made available to hospitals during the first three months of commercialisation. The figure comes from the company’s internal data.

In which countries is REIG JOFRE marketing dalbavancin?

REIG JOFRE has made dalbavancin available through affiliates in the United Kingdom, Spain, France, Poland and Sweden, and has a presence in nine European countries. The treatment is also available in other European countries through commercial agreements.

Which country is currently the leading market for REIG JOFRE’s dalbavancin launch?

The United Kingdom is the leading market for REIG JOFRE’s dalbavancin launch at this initial stage. The company said the launch began with particular momentum there, alongside Spain, France, Poland and Sweden.

Where is REIG JOFRE’s dalbavancin manufactured?

REIG JOFRE manufactures dalbavancin at its Barcelona facility. The company markets it through its affiliates and under licensing agreements.

What is dalbavancin used to treat?

Dalbavancin is an injectable antibiotic for hospital use indicated for the treatment of acute bacterial skin and skin structure infections in adults. It is available on prescription only.

How does REIG JOFRE’s dalbavancin launch fit into its hospital business?

Dalbavancin joins REIG JOFRE’s hospital portfolio within the anti-infectives therapeutic area. The company said the addition contributes to expanding its international hospital business in anti-infectives.

How does REIG JOFRE describe its business?

REIG JOFRE describes itself as a pan-European pharmaceutical company that develops, manufactures and markets essential healthcare solutions. It is listed on the Spanish Stock Exchange’s continuous market under the ticker BME:RJF.

What did REIG JOFRE CEO Ignasi Biosca say about the dalbavancin launch?

Ignasi Biosca, CEO of REIG JOFRE, said the addition of dalbavancin forms part of the company’s growth strategy in hospital anti-infectives. He said the launch reflects REIG JOFRE’s ability to develop, manufacture and make essential medicines available to European healthcare systems in highly specialised therapeutic areas.

What other operational milestones did REIG JOFRE highlight alongside the dalbavancin launch?

REIG JOFRE identified the dalbavancin launch as one of its key operational milestones in the first quarter of 2026. The company also highlighted progress on new production lines and continued advancement in the biotechnology integration of Leanbio and Syna Therapeutics.

Home
News Intelligence
Laboratorio Reig Jofre S.A.
REIG JOFRE begins European marketing of dalbavancin across nine countries

Back to all Laboratorio Reig Jofre S.A. press releases

Laboratorio Reig Jofre S.A.

BME:RJF

REIG JOFRE begins European marketing of dalbavancin across nine countries

Published Wednesday, 10 June 2026

Get alerts

Plain English summaries when Laboratorio Reig Jofre S.A. announces news.

At a glance

Company: Laboratorio Reig Jofre S.A.
Listings: BME:RJF
Announcement type: Product launch
Published: Wednesday, 10 June 2026
Source announcement: reigjofre.com

Key figures
Measure	Figure	Period
Vials made available to hospitals	nearly 20,000 vials	the first three months of commercialization

Figures are quoted from this announcement and selected automatically.

FAQSIR Generated from this announcement View original release below for safe harbor and regulatory notices

Announcement Summary

REIG JOFRE (BME:RJF) has begun marketing dalbavancin in Europe. The prescription-only injectable antibiotic is for hospital use and is indicated to treat acute bacterial skin and skin structure infections in adults. It joins the company’s hospital anti-infectives portfolio.

The launch covers nine European countries. REIG JOFRE has made dalbavancin available through affiliates in the United Kingdom, Spain, France, Poland and Sweden, and through commercial agreements in other European markets. The medicine is manufactured at the company’s Barcelona facility and marketed through affiliates and licensing agreements. In the first three months, nearly 20,000 vials were made available to hospitals. The company says the United Kingdom was the leading market at this initial stage.

Investor FAQs

REIG JOFRE announced that it has begun marketing dalbavancin in Europe as part of its hospital anti-infectives portfolio. The prescription-only injectable antibiotic is indicated for treating acute bacterial skin and skin structure infections in adults.

Source announcement

Company: Laboratorio Reig Jofre S.A.
Title: REIG JOFRE strengthens its hospital anti-infectives portfolio with the launch of dalbavancin in Europe
Published: Wednesday, 10 June 2026
Source site: reigjofre.com

Read the source announcement on reigjofre.com

FAQSIR's summary and investor FAQs are generated by AI from the text of this announcement alone, without information from other sources.

Figures, forecasts and other claims are the announcement's, not FAQSIR's. FAQSIR does not independently verify them.

Read the original press release

Full text as published, unedited.

Loading the original release…

Important Notice And Disclaimer

This article was generated by an artificial intelligence system from an announcement published by the issuer. It has not been independently researched, verified, or edited by a journalist, and no person holds editorial responsibility for its wording.

The issuer named in this article has not paid for this page and has no commercial relationship with its publisher. This is an unpaid evaluation preview produced from announcements the issuer published publicly, and it is not independent editorial coverage.

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

Ask about this announcement

Answers drawn only from this announcement

Reading the announcement…